7TM Pharma announces positive results with promising compound  

2006.03.23
Biotech company 7TM Pharma, based north of Copenhagen has announced positive results from a clinical phase I/II study with its promising compound TM30338 for the treatment of obesity

Biotech company 7TM Pharma, based north of Copenhagen has announced positive results from a clinical phase I/II with its promising compound TM30338 for the treatment of obesity. 7TM Pharma writes in a press release that the study demonstrated that the drug candidate is safe and well tolerated in humans.

Thue Schwartz, research director of 7TM Pharma says: "We have all the green lights to continue with the project. We expect to initiate phase II trials this year to get absolute proof of concept". The biotech firm also plans to start phase I/II studies this year with another compound, TM30339, for the treatment of obesity.

7TM is expected to need more capital from current and new investors as it advances its drug development. Current investors include Novo A/S, Index Ventures, Johnson & Johnson Development Corporation, the venture capital subsidiary of Johnson & Johnson. The news was reported by national daily newspaper Jyllands-Posten.

7TM Pharma is a drug discovery and development company which has a pipeline of advanced programmes in its main therapeutic focus area, obesity. The biotech company's pipeline also includes programmes on well validated targets in allergy/inflammation, therapeutic angiogenesis and cardiovascular diseases. Last year, 7TM entered research agreements with Procter & Gamble Pharmaceuticals and Ortho-McNeil, a Johnson & Johnson subsidiary.

Link > 7TM Pharma 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×